What You Should Know:
– RxVantage has acquired onPoint Oncology to provide cancer care teams with on-demand access to educational resources, reimbursement data, and analytics.
– The acquisition of onPoint Oncology builds on RxVantage’s rapidly expanding digital offerings for providers. In April, RxVantage launched Virtual Meetings to help providers reestablish access to life science experts amidst the disruptions caused by COVID-19.
RxVantage, the leading digital platform connecting healthcare providers to educational resources and experts from life science companies, today announced the acquisition of onPoint Oncology, the leader in oncology reimbursement data and analytics.
The partnership ensures that care teams will have access to onPoint’s unique revenue cycle data and reimbursement insights as well as one-click access to educational resources and expertise from any life science company, all through the free RxVantage digital platform.
The acquisition of onPoint Oncology builds on RxVantage’s rapidly expanding digital offerings for providers. In April, RxVantage launched Virtual Meetings to help providers reestablish access to life science experts amidst the disruptions caused by COVID-19.
onPoint will operate as a wholly-owned subsidiary of RxVantage. As part of the acquisition, industry veterans Tracy Lewis and Bobbi Buell will join RxVantage leadership team. Financial details of the acquisition were not disclosed.
RxVantage Background
Founded in 2007, RxVantage’s mission is to ensure that every provider has the most relevant information and data on medications and medical technologies, in order to deliver the best care to every patient. More than 6,000 medical practices across the US utilize RxVantage to connect and engage with over 50,000 experts from life science companies.
